ReviewImmunological reviews2020
Advances in genetics toward identifying pathogenic cell states of rheumatoid arthritis.
Review in Immunological reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Gut Microbes as the Major Drivers of Rheumatoid Arthritis: Our Microbes Are Our Fortune!Microorganisms · 2025Review
- Recent Advances in Biomimetic Drug Delivery for Rheumatoid Arthritis Treatment.International journal of nanomedicine · 2025Review
- Genetic Polymorphisms in Exon 5 and Intron 5 and 7 ofBiology · 2024Article
- The chromatin landscape of pathogenic transcriptional cell states in rheumatoid arthritis.Nature communications · 2024Article
- Gut microbial metabolite targets HDAC3-FOXK1-interferon axis in fibroblast-like synoviocytes to ameliorate rheumatoid arthritis.Bone research · 2024Article
- Non-coding autoimmune risk variant defines role for ICOS in T peripheral helper cell development.Nature communications · 2024Article
- Mapping the functional impact of non-coding regulatory elements in primary T cells through single-cell CRISPR screens.Genome biology · 2024Article
- Prodrug-based nanomedicines for rheumatoid arthritis.Discover nano · 2024Review
- The Chromatin Landscape of Pathogenic Transcriptional Cell States in Rheumatoid Arthritis.bioRxiv : the preprint server for biology · 2023Article
- Expression of Non-T Cell Activation Linker (NTAL) in Jurkat Cells Negatively Regulates TCR Signaling: Potential Role in Rheumatoid Arthritis.International journal of molecular sciences · 2023Article
- Immunosenescence of T cells: a key player in rheumatoid arthritis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Review
- Granzyme KScience translational medicine · 2022Article
- Integrative analysis of DNA methylation and gene expression data for the diagnosis and underlying mechanism of Parkinson's disease.Frontiers in aging neuroscience · 2022Article
- T cell transgressions: Tales of T cell form and function in diverse disease states.International reviews of immunology · 2022Review
- Genetics and functional genetics of autoimmune diseases.Seminars in immunopathology · 2022Article
- Association of CD40 Gene Polymorphisms With Systemic Lupus Erythematosus and Rheumatoid Arthritis in a Chinese Han Population.Frontiers in immunology · 2021Article
- The immunology of rheumatoid arthritis.Nature immunology · 2021Review
- Improving the trans-ancestry portability of polygenic risk scores by prioritizing variants in predicted cell-type-specific regulatory elements.Nature genetics · 2020Article
- Latin American Genes: The Great Forgotten in Rheumatoid Arthritis.Journal of personalized medicine · 2020Review
- Regulating Gut Microbiome: Therapeutic Strategy for Rheumatoid Arthritis During Pregnancy and Lactation.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Rheumatoid arthritis (RA) risk has a large genetic component (~60%) that is still not fully understood. This has hampered the design of effective treatments that could promise lifelong remission. RA is a polygenic disease with 106 known genome-wide significant associated loci and thousands of small effect causal variants. Our current understanding of RA risk has suggested cell-type-specific contexts for causal variants, implicating CD4 + effector memory T cells, as well as monocytes, B cells and stromal fibroblasts. While these cellular states and categories are still mechanistically broad, future studies may identify causal cell subpopulations. These efforts are propelled by advances in single cell profiling. Identification of causal cell subpopulations may accelerate therapeutic intervention to achieve lifelong remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.